Rani Therapeutics Holdings, Inc.
RANI
NASDAQ·Healthcare·Biotechnology·Mkt cap $56.5M
$0.87
▲ +1.54%
P/E
-10.94
Mkt Cap
$56.5M
52-Wk Range
$0.45–$3.87
52-Week Range
$0.45 - $3.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 73.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+4.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RANI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.04 vs -$0.05 consensus (+20.0% surprise). Revenue of $1.7M vs $925.0K expected (+84.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.0%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$1.7M
$0
Margins · last 2Q
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 21, 2026
vs Industry
How RANI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.